Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort.

Dementia with Lewy bodies Lewy body disease Mild cognitive impairment Mild neurocognitive impairment Prodromal Subjective cognitive impairment

Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
19 07 2022
Historique:
received: 02 02 2022
accepted: 11 06 2022
entrez: 19 7 2022
pubmed: 20 7 2022
medline: 22 7 2022
Statut: epublish

Résumé

Isolated subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) are the prodromal phases of dementia with Lewy bodies (DLB). MEMENTO is a nationwide study of patients with SCI and MCI with clinic, neuropsychology, biology, and brain imaging data. We aimed to compare SCI and MCI patients with symptoms of prodromal DLB to others in this study at baseline. Participants of the French MEMENTO cohort study were recruited for either SCI or MCI. Among them, 892 were included in the Lewy sub-study, designed to search specifically for symptoms of DLB. Probable prodromal DLB diagnosis (pro-DLB group) was done using a two-criteria cutoff score among the four core clinical features of DLB. This Pro-DLB group was compared to two other groups at baseline: one without any core symptoms (NS group) and the one with one core symptom (1S group). A comprehensive cognitive battery, questionnaires on behavior, neurovegetative and neurosensory symptoms, brain 3D volumetric MRI, CSF, FDG PET, and amyloid PET were done. The pro-DLB group comprised 148 patients (16.6%). This group showed more multidomain (59.8%) MCI with slower processing speed and a higher proportion of patients with depression, anxiety, apathy, constipation, rhinorrhea, sicca syndrome, and photophobia, compared to the NS group. The pro-DLB group had isolated lower P-Tau in the CSF (not significant after adjustments for confounders) and on brain MRI widening of sulci including fronto-insular, occipital, and olfactory sulci (FDR corrected), when compared to the NS group. Evolution to dementia was not different between the three groups over a median follow-up of 2.6 years. Patients with symptoms of prodromal DLB are cognitively slower, with more behavioral disorders, autonomic symptoms, and photophobia. The occipital, fronto-insular, and olfactory bulb involvement on brain MRI was consistent with symptoms and known neuropathology. The next step will be to study the clinical, biological, and imaging evolution of these patients. Clinicaltrials.gov , NCT01926249.

Sections du résumé

BACKGROUND
Isolated subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) are the prodromal phases of dementia with Lewy bodies (DLB). MEMENTO is a nationwide study of patients with SCI and MCI with clinic, neuropsychology, biology, and brain imaging data. We aimed to compare SCI and MCI patients with symptoms of prodromal DLB to others in this study at baseline.
METHODS
Participants of the French MEMENTO cohort study were recruited for either SCI or MCI. Among them, 892 were included in the Lewy sub-study, designed to search specifically for symptoms of DLB. Probable prodromal DLB diagnosis (pro-DLB group) was done using a two-criteria cutoff score among the four core clinical features of DLB. This Pro-DLB group was compared to two other groups at baseline: one without any core symptoms (NS group) and the one with one core symptom (1S group). A comprehensive cognitive battery, questionnaires on behavior, neurovegetative and neurosensory symptoms, brain 3D volumetric MRI, CSF, FDG PET, and amyloid PET were done.
RESULTS
The pro-DLB group comprised 148 patients (16.6%). This group showed more multidomain (59.8%) MCI with slower processing speed and a higher proportion of patients with depression, anxiety, apathy, constipation, rhinorrhea, sicca syndrome, and photophobia, compared to the NS group. The pro-DLB group had isolated lower P-Tau in the CSF (not significant after adjustments for confounders) and on brain MRI widening of sulci including fronto-insular, occipital, and olfactory sulci (FDR corrected), when compared to the NS group. Evolution to dementia was not different between the three groups over a median follow-up of 2.6 years.
CONCLUSIONS
Patients with symptoms of prodromal DLB are cognitively slower, with more behavioral disorders, autonomic symptoms, and photophobia. The occipital, fronto-insular, and olfactory bulb involvement on brain MRI was consistent with symptoms and known neuropathology. The next step will be to study the clinical, biological, and imaging evolution of these patients.
TRIAL REGISTRATION
Clinicaltrials.gov , NCT01926249.

Identifiants

pubmed: 35854388
doi: 10.1186/s13195-022-01037-0
pii: 10.1186/s13195-022-01037-0
pmc: PMC9295361
doi:

Banques de données

ClinicalTrials.gov
['NCT01926249']

Types de publication

Clinical Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

96

Informations de copyright

© 2022. The Author(s).

Références

Dement Geriatr Cogn Disord. 2011;31(4):309-16
pubmed: 21502762
Neurology. 2020 Apr 28;94(17):743-755
pubmed: 32241955
Brain. 2019 Mar 1;142(3):744-759
pubmed: 30789229
Alzheimers Res Ther. 2015 Jun 01;7(1):30
pubmed: 26034513
J Alzheimers Dis. 2011;27(1):39-47
pubmed: 21725162
PLoS One. 2012;7(11):e48953
pubmed: 23152828
Psychogeriatrics. 2009 Jun;9(2):56-61
pubmed: 19604326
Psychol Med. 2019 Feb;49(3):396-402
pubmed: 29692275
Neuroinformatics. 2016 Jul;14(3):253-64
pubmed: 27066973
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Neurology. 2011 Aug 30;77(9):875-82
pubmed: 21849645
Mov Disord. 2010 Apr 30;25(6):763-6
pubmed: 20437542
Alzheimers Res Ther. 2020 Sep 29;12(1):120
pubmed: 32993772
J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):387-91
pubmed: 17557796
J Geriatr Psychiatry Neurol. 2016 Sep;29(5):249-53
pubmed: 27502299
Neuroimage. 2009 Jul 1;46(3):749-61
pubmed: 19236922
Neurology. 2004 Jan 27;62(2):181-7
pubmed: 14745051
Mov Disord. 2020 May;35(5):859-867
pubmed: 32048343
ISRN Neurol. 2013 Sep 19;2013:501327
pubmed: 24224097
Psychogeriatrics. 2013 Jun;13(2):128-38
pubmed: 23909972
Br J Psychiatry. 2000 Sep;177:252-6
pubmed: 11040887
Curr Opin Neurol. 2010 Aug;23(4):359-67
pubmed: 20489617
Alzheimers Res Ther. 2017 Aug 29;9(1):67
pubmed: 28851447
J Neurol Neurosurg Psychiatry. 2018 May;89(5):467-475
pubmed: 29321140
Dis Colon Rectum. 2006 Feb;49(2):219-27
pubmed: 16362804
Brain. 2019 Jul 1;142(7):2051-2067
pubmed: 31111143
Alzheimers Res Ther. 2016 Jul 20;8:31
pubmed: 27484179
Ann Nucl Med. 2018 Feb;32(2):75-86
pubmed: 29218458
J Alzheimers Dis. 2018;64(2):543-549
pubmed: 29889069
Neuroimage. 2009 May 1;45(4):1107-16
pubmed: 19349228
Dement Geriatr Cogn Disord. 2012;33(4):273-81
pubmed: 22722638
Neurology. 2013 Feb 26;80(9):810-3
pubmed: 23365056
Acta Neuropathol. 2009 Jun;117(6):613-34
pubmed: 19399512
Geriatr Psychol Neuropsychiatr Vieil. 2017 Dec 1;15(4):434-442
pubmed: 29187334
Front Neurol. 2018 Nov 27;9:999
pubmed: 30538666
Nat Rev Neurol. 2019 Aug;15(8):437-438
pubmed: 31152151
Alzheimers Res Ther. 2017 Mar 16;9(1):19
pubmed: 28302161
Neurology. 2013 Dec 3;81(23):2032-8
pubmed: 24212390
Sci Rep. 2017 Aug 25;7(1):9437
pubmed: 28842567
PLoS One. 2015 Jun 10;10(6):e0127396
pubmed: 26061655

Auteurs

Frederic Blanc (F)

CM2R (Memory Resource and Research Centre), Day Hospital, Geriatrics Department, University Hospital of Strasbourg, Strasbourg, France. f.blanc@unistra.fr.
CNRS, ICube Laboratory, UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), Team IMIS, University of Strasbourg, Strasbourg, France. f.blanc@unistra.fr.

Vincent Bouteloup (V)

CHU de Bordeaux, Pôle de santé publique, Bordeaux, France.
Centre INSERM U1219, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Bordeaux School of Public Health, Université de Bordeaux, Bordeaux, France.

Claire Paquet (C)

CM2R of Paris Nord, AP-HP, Groupe Hospitalier Saint-Louis Lariboisière Fernand Widal, Paris, France.

Marie Chupin (M)

CATI Multicenter Neuroimaging Platform, Saclay, France.

Florence Pasquier (F)

INSERM U1171 and CM2R of Lille, CHRU de Lille, Hôpital Roger Salengro, University of Lille, Lille, France.

Audrey Gabelle (A)

CM2R of Montpellier, CHU de Montpellier, Hôpital Gui de Chauliac, Montpellier, France.

Mathieu Ceccaldi (M)

CM2R of Marseille, CHU de Marseille, Hôpital La Timone, Marseille, France.

Paulo Loureiro de Sousa (PL)

CNRS, ICube Laboratory, UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), Team IMIS, University of Strasbourg, Strasbourg, France.

Pierre Krolak-Salmon (P)

CM2R of Lyon, Hospices Civils de Lyon, Hôpital des Charpennes, Lyon, France.

Renaud David (R)

CM2R of Nice, CHU de Nice, Institut Claude Pompidou, EA 7276 CoBTeK "Cognition Behaviour Technology", Nice, France.

Clara Fischer (C)

CATI Multicenter Neuroimaging Platform, Saclay, France.

Jean-François Dartigues (JF)

CHU de Bordeaux, Pôle de santé publique, Bordeaux, France.
CM2R of Bordeaux, CHU de Bordeaux, Hôpital Pellegrin, Bordeaux, France.

David Wallon (D)

CM2R of Rouen, Neurology Department, Rouen University Hospital, Rouen, France.

Olivier Moreaud (O)

CM2R of Grenoble, CHU de Grenoble Alpes, Hôpital de la Tronche, Grenoble, France.

Mathilde Sauvée (M)

CM2R of Grenoble, CHU de Grenoble Alpes, Hôpital de la Tronche, Grenoble, France.

Catherine Belin (C)

Memory Clinic, Hôpital Avicenne, AP-HP, Hôpitaux Universitaires, Paris-Seine-Saint-Denis, Bobigny, France.

Sandrine Harston (S)

CM2R of Bordeaux, CHU de Bordeaux, Hôpital Xavier Arnozan, Bordeaux, France.

Anne Botzung (A)

CM2R (Memory Resource and Research Centre), Day Hospital, Geriatrics Department, University Hospital of Strasbourg, Strasbourg, France.

Timothée Albasser (T)

CM2R (Memory Resource and Research Centre), Day Hospital, Geriatrics Department, University Hospital of Strasbourg, Strasbourg, France.

Catherine Demuynck (C)

CM2R (Memory Resource and Research Centre), Day Hospital, Geriatrics Department, University Hospital of Strasbourg, Strasbourg, France.

Izzie Namer (I)

CNRS, ICube Laboratory, UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), Team IMIS, University of Strasbourg, Strasbourg, France.

Marie-Odile Habert (MO)

CATI Multicenter Neuroimaging Platform, Saclay, France.

Stéphane Kremer (S)

CNRS, ICube Laboratory, UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), Team IMIS, University of Strasbourg, Strasbourg, France.

Olivier Bousiges (O)

CM2R (Memory Resource and Research Centre), Day Hospital, Geriatrics Department, University Hospital of Strasbourg, Strasbourg, France.

Marc Verny (M)

CM2R Île-de-France Sud and Geriatrics Centre, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
Université Pierre et Marie Curie et DHU FAST, UMR 8256 (CNRS), Paris, France.

Candice Muller (C)

CM2R (Memory Resource and Research Centre), Day Hospital, Geriatrics Department, University Hospital of Strasbourg, Strasbourg, France.

Nathalie Philippi (N)

CM2R (Memory Resource and Research Centre), Day Hospital, Geriatrics Department, University Hospital of Strasbourg, Strasbourg, France.
CNRS, ICube Laboratory, UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), Team IMIS, University of Strasbourg, Strasbourg, France.

Geneviève Chene (G)

CHU de Bordeaux, Pôle de santé publique, Bordeaux, France.
Centre INSERM U1219, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Bordeaux School of Public Health, Université de Bordeaux, Bordeaux, France.

Benjamin Cretin (B)

CM2R (Memory Resource and Research Centre), Day Hospital, Geriatrics Department, University Hospital of Strasbourg, Strasbourg, France.
CNRS, ICube Laboratory, UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), Team IMIS, University of Strasbourg, Strasbourg, France.

Jean-François Mangin (JF)

CATI Multicenter Neuroimaging Platform, Saclay, France.
NeuroSpin, I2BM, Commissariat à l'Énergie Atomique, Université Paris-Saclay, Saclay, France.

Carole Dufouil (C)

CHU de Bordeaux, Pôle de santé publique, Bordeaux, France.
Centre INSERM U1219, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Bordeaux School of Public Health, Université de Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH